Introduction {#Sec1}
============

The incidence and prevalence of colorectal cancer (CRC) have been increasing in recent decades in Taiwan \[[@CR1]\]. In addition to perioperative radiotherapy, chemotherapy, or both, surgical resection plus lymph node dissection (LND) plays a key role in operable CRCs \[[@CR2]\]. Currently, the T/N/M status and cancer stage defined in the American Joint Committee on Cancer (AJCC) manual, 8th edition, remain the cornerstones to classify and tailor optimal treatment modalities for CRC patients \[[@CR3], [@CR4]\].

Concerning metastasis in the regional lymph nodes (i.e., the nodal positive condition), the AJCC TNM staging system emphasizes the number of positive dissected lymph nodes (PDLNs). The N status (AJCC 8th edition staging system) has been classified as N0, N1a, N1b, N2a, and N2b (stepwise) based on the number of PDLNs (0, 1, 2--3, 4--6, and more than 7, respectively) because of their predictive power for survival \[[@CR3], [@CR4]\]. Although a minimal requirement of 12 total dissected lymph nodes (TDLNs) is suggested, controversy exists regarding the extent to which LND should be performed \[[@CR3], [@CR4]\]. Some researchers emphasize that extensive LND can achieve better local-regional control, eliminate undetectable lesions, and perhaps prolong survival; some researchers emphasize that extensive LND can achieve accurate N staging; and others believe that extensive LND may increase the risk of postoperative comorbidities without improving survival \[[@CR5], [@CR6]\].

The extent of LND, which is represented and quantified by the number of TDLNs, is crucial for an accurate N status determination. To distinguish nodal negative (N(−)) from nodal positive (N(+)) CRC patients and to further subgroup the severity of N(+) patients, LND with sufficient TDLNs appears to be mandatory. In the current study, we reappraised the impact of LND/TDLNs on CRC patients.

Materials and methods {#Sec2}
=====================

Recruitment of CRC patients {#Sec3}
---------------------------

This was a retrospective study, and the subjects were retrieved from a computerized database from a single medical institution, Taipei Hospital, Ministry of Health and Welfare, Taiwan, between Jan 2008 and Dec 2010. In this period of time, 82 patients underwent upfront surgical resections for colorectal tumors, including 80 primary CRCs over the colorectal region, 1 carcinoma in situ (Tis) over the transverse colon, and 1 gastrointestinal stromal tumor (GIST) over the rectum. Among the 80 CRC patients, 7 were excluded from the analysis for the following reasons: 2 were lost to follow-up after being discharged from the hospital, 3 died within 1 month after surgery, 1 had synchronous CRCs over the sigmoid colon and rectum, and 1 had synchronous CRCs over the transverse and sigmoid colons. Ultimately, a total of 73 constitutive patients with operable CRCs and no obvious distant organ metastasis during the preoperative assessment received surgical resection as the primary treatment modality. Postoperative adjuvant radiotherapy, chemotherapy, or both were scheduled if clinically indicated. The Institute Review Board of Taipei Hospital approved this study. All of the patients were completely followed until June 2019.

Preoperative workup {#Sec4}
-------------------

Preoperative workup included plain chest radiography, abdominal computed tomography (CT) scans from the lower chest to pelvis, a colorectal endoscopic examination, a complete blood count and cell differentials of leukocytes in the peripheral blood, routine urine tests, blood biochemistries, and EKG/cardiac sonography to assess each patient's general and oncological conditions. A whole-body bone scan or a CT/MRI scan of the brain was performed if clinically indicated. These patients were subjected to surgical resection if they agreed and had no contraindication for surgical resection.

Pathological examination {#Sec5}
------------------------

After examination by a pathologist, the surgical-pathological T/N/M statuses of the 73 CRC patients were confirmed and revised according to the AJCC 8th edition staging system \[[@CR3], [@CR4]\]. In addition, the maximal tumor diameter, primary tumor location, conditions of lymphatic vessel invasion, venous vessel invasion or perineural invasion, and histological grade of cancer cell malignancy were recorded if available.

Concerning the N status, we recoded the numbers of TDLNs and PDLNs for all CRC patients. We defined the positive rate as the number of PDLNs divided by the number of TDLNs (= PDLNs/TDLNs, %) for each CRC patient. We also defined the number of negative dissected lymph nodes (NDLNs) as the number of TDLNs minus the number of PDLNs (NDLNs = TDLNs − PDLNs) for each CRC patient.

Prognostic variables {#Sec6}
--------------------

The potential and reported prognostic variables, including sex, age, and maximal tumor diameter, as well as the pathological findings, were recorded and analyzed. The impacts of TDLNs and NDLNs were also evaluated.

Statistical analysis {#Sec7}
--------------------

SPSS statistical software version 17 (SPSS Inc., Chicago, IL) was used for data analyses in this retrospective study. The continuous variables between two or among three groups were compared using Student's *t* test/the Mann--Whitey *U* test or ANOVA/the Kruskal-Wallis *H* test when appropriate. The categorical variables between two groups were compared using the chi-square test. Overall survival was measured from the date of surgery to the date of death or the last follow-up in June 2019. Survival curves of the patients were calculated and plotted by the Kaplan--Meier method. The log-rank test was used to compare survival probabilities among different levels within each categorical variable, and the univariate Cox proportional hazards regression method was used to investigate their relative hazard ratios (HRs). In addition to sex and age, variables associated with survival probability at a significance level of 0.1 or less in the log-rank test were also included in the multivariate Cox proportional hazards regression model. The optimal cutoff number of TDLNs to detect the N2b status (i.e., 7 or more PDLNs, ≤ 7 vs. \> 7) among nodal positive N(+) CRC patients was determined by receiver operating characteristic (ROC) curves through the area under the curve (AUC) and the Youden index. Significance was defined as *p* \< 0.05.

Results {#Sec8}
=======

Demographic data {#Sec9}
----------------

A total of 73 CRC patients (female/male, 30/43) with a mean age of 65.3 years were retrospectively evaluated, and their demographic data are listed in Table [1](#Tab1){ref-type="table"}. Concerning the primary tumor locations, there were 4 (5.5%), 13 (17.8%), 15 (20.5%), 6 (8.2%), 19 (26.0%), and 16 (21.9%) in the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum, respectively. Concerning the types of surgical resections, there were 4 (5.5%), 25 (34.2%), 6 (8.2%), 9 (12.3%), 22 (30.1%), 2 (2.7%), 2 (2.7%), and 3 (4.1%) CRC patients undergoing segmental resection, right hemicolectomy, left hemicolectomy, anterior resection, lower anterior resection, subtotal colectomy, abdominal-perineal resection, and Hartmann's procedure, respectively. Concerning the pathological T/N/M status and cancer stage, there were 4 (5.5%)/9 (12.3%)/56 (76.7%)/4 (5.5%) patients with the T1/T2/T3/T4 status, respectively; 31 (42.5%)/17 (23.3%)/25 (34.2%) patients with the N0/N1/N2 status, respectively; 67 (91.8%)/6 (8.2%) patients with the M0/M1 status, respectively; and 12 (16.4%)/19 (26.0%)/36 (49.3%)/6 (8.2%) patients in stages I/II/III/IV, respectively. The mean maximal tumor diameter was 5.1 cm, and 22 (30.1%), 11 (15.1%), and 4 (5.5%) tumors had lymphatic vessel invasion, venous vessel invasion, and perineural invasion, respectively. Concerning the histological grade, there were 51 (69.9%), 16 (21.9%), and 6 (8.2%) CRCs presenting low, intermediate, and high grades of cancer cell malignancy, respectively. Concerning the distribution of TDLNs, the mean, 25th percentile, 50th percentile (median), and 75th percentile were 20.7, 10, 19, and 28.5, respectively. Concerning the distribution of PDLNs and the positive rate, their means were 3.6 and 18.1%, respectively. Concerning the distribution of NDLNs, the mean, 25th percentile, 50th percentile (median), and 75th percentile were 17.2, 9, 15, and 26.5, respectively. The mean overall survival and follow-up periods were 91.6 and 70.0 months, respectively. Table 1Demographic data of the 73 CRC patientsVariablesMean ± SD/number (%)Gender Female/Male30 (41.1)/43 (58.9)Age (years)65.3 ± 11.2Tumor location Cecum4 (5.5) Ascending colon13 (17.8) Transverse colon15 (20.5) Descending colon6 (8.2) Sigmoid colon19 (26.0) Rectum16 (21.9)Type of surgical resection Segmental resection4 (5.5) Right hemicolectomy25 (34.2) Left hemicolectomy6 (8.2) Anterior resection9 (12.3) Lower anterior resection22 (30.1) Sub-total colectomy2 (2.7) Abdominal-perineal resection2 (2.7) Hartmann's procedure3 (4.1)Tumor configuration Exophytic/ulcerative25 (34.2)/48 (65.8)Pathological findingsT/N/M status and cancer stage, AJCC8thT-status T1/T2/T3/T44 (5.5)/9 (12.3)/56 (76.7)/4 (5.5)N-status N0/N1/N231 (42.5)/17 (23.3)/25 (34.2)M-status M0/M167 (91.8)/6 (8.2)Stage I/II/III/IV12 (16.4)/19 (26.0)/36 (49.3)/6 (8.2)Maximal tumor diameter (cm)5.1 ± 2.6Lymphatic vessel invasion No/yes/not analyzed42 (57.5)/22 (30.1)/9 (12.3)Venous vessel invasion No/yes/not analyzed52 (71.2)/11 (15.1)/10 (13.7)Perineural invasion No/yes/not analyzed53 (72.6)/4 (5.5)/16 (21.9)Histological grade Low/intermediate/high grade51 (69.9)/16 (21.9)/6 (8.2)No. of TDLNs (25, 50, and 75 percentile)20.7 ± 11.8 (10, 19, and 28.5)No. of PDLNs (25, 50, and 75 percentile)3.6 ± 5.2 (0, 1 and 5)Positive rate18.1 ± 23.6No. of NDLNs (25, 50, and 75 percentile)17.2 ± 11.2 (9, 15, and 26.5)Follow-up period (mean, 95%CI) (months)70.0 (59.5--80.5)Overall survival (mean, 95%CI) (months)91.6 (78.6--105.5)*CRC* colorectal cancer, *No*. number, *TDLNs* total dissected lymph nodes, *PDLNs* positive dissected lymph nodes, *NDLNs* negative dissected lymph nodes, *Positive rate* No. PDLNs/No. TDLNs, %, *SD* standard deviation

Prognostic variables and their HRs for all CRC patients {#Sec10}
-------------------------------------------------------

Among the 73 CRC patients, we found that the T status (*p* = 0.074), N status (*p* \< 0.001), M status (*p* \< 0.001), stage (*p* \< 0.001), lymphatic vessel invasion (*p* = 0.001), venous vessel invasion (*p* = 0.001), perineural invasion (*p* = 0.037), histological grade of cancer cell malignancy (*p* = 0.022), and numbers of NDLNs (*p* = 0.071) were prognostic variables for survival (Table [2](#Tab2){ref-type="table"}). Table 2Prognostic variables, survivals, and their hazard ratios (HRs) of the 73 CRC patientsPrognostic variablesSurvival differencesCox's proportional hazards regressionSurvival, monthsLog-rankUnivariateMultivariateMean (95% CI)*p* valueHR (95% CI)*p* valueHR (95% CI)*p* valueGender0.361 Female (*n* = 30)81.3 (61.3--101.2)1.0001.000 Male (*n* = 43)97.5 (81.2--113.9)0.715 (0.347--1.475)0.3642.354 (0699--7.929)0.167Age (years)0.592 ≤65 (*n* = 44)87.1 (70.9--103.2)1.003 (0.973--1.035)\*0.6491.039 (0.981--1.102)\*0.193 \>65 (*n* = 29)94.8 (74.6--115.1)\--Maximal tumor diameter (cm)0.132 ≤5 (*n* = 44)94.2 (79.4--108.9)1.000 \>5 m (*n* = 29)78.4 (57.4--99.5)1.726 (0.841--3.544)0.137T-status0.074 T1/T2 (*n* = 13)114.5 (95.8--133.2)1.0001.000 T3 (*n* = 56)87.9 (73.0--102.9)3.221 (0.762--13.612)0.1120.431 (0.067--2.768)0.375 T4 (*n* = 5)51.4 (9.8--92.9)7.100 (1.179--42.754)0.0320.316 (0.023--4.304)0.387N-status\< 0.001 N0 (*n* = 31)127.1 (115.9--138.3)1.0001.000 N1 (*n* = 17)86.0 (62.3--109.6)5.267 (1.396--19.863)0.0145.749 (0.959--34.480)0.056 N2 (*n* = 25)50.9 (31.0--70.8)12.896 (3.793--43.843)\< 0.00117.677 (2.048--152.605)0.009M-status\< 0.001 M0 (*n* = 67)98.5 (85.6--111.4)1.0001.000 M1 (*n* = 6)16.2 (3.7--28.7)7.708 (2.957--20.095)\< 0.0017.517 (1.626--34.756)0.010Stage\< 0.001 I (*n* = 12)113.6 (93.3--133.9)1.000 II (*n* = 19)132.2 (122.2--142.2)0.284 (0.026--3.128)0.303 III (*n* = 36)74.6 (56.9--92.3)4.100 (0.959--17.521)0.057 IV (*n* = 6)16.2 (3.7--28.7)18.011 (3.476--93.338)0.001Lymphatic vessel invasion0.001 No (*n* = 42)100.1 (86.7--113.6)1.0001.000 Yes (*n* = 22)52.8 (31.9--73.6)3.276 (1.509--7.114)0.0030.832 (0.226--3.060)0.782Venous vessel invasion0.001 No (*n* = 52)94.4 (81.1--107.7)1.0001.000 Yes (*n* = 11)39.2 (16.8--61.6)3.782 (1.590--8.993)0.0032.828 (0.398--20.120)0.299Perineural invasion0.037 No (*n* = 53)90.5 (76.7--104.2)1.0001.000 Yes (*n* = 4)33.7 (0.0--72.0)3.402 (0.996--11.625)0.0511.702 (0.192--15.084)0.633Histological grade0.022 Low grade (*n* = 51)94.9 (81.0--108.8)1.0001.000 Intermediate/high grade (*n* = 22)71.2 (48.8--93.6)2.266 (1.103--4.656)0.0262.332 (0.814--6.680)0.115Tumor configuration0.104 Exophytic (*n* = 25)104.1 (87.9--120.3)1.000 Ulcerative (*n* = 48)82.7 (66.1--99.3)1.991 (0.853--4.646)0.111No. of TDNLs0.448 ≤ 10 (25 percentile, *n* = 20)88.1 (66.0--110.3)1.783 (0.548--5.803)0.337 10--29 (25--75 percentile, *n* = 37)85.1 (66.4--103.7)1.998 (0.671--5.950)0.214 \> 29 (75 percentile, *n* = 16)97.7 (74.8--121.1)1.000No. of NDLNs0.071 ≤ 9 (25 percentile, *n* = 22)69.8 (48.1--91.5)2.661 (0.956--7.405)0.0610.727 (0.153--3.448)0.688 9--27 (25--75 percentile, *n* = 33)98.3 (79.0--117.5)1.300 (0.451--3.752)0.6270.406 (0.074--2.223)0.299 \> 27 (75 percentile, *n* = 18)97.4 (76.5--118.2)1.0001.000*CRC* colorectal cancer, *No.* number, *TDLNs* total dissected lymph nodes, *NDLNs* negative dissected lymph nodes, *SD* standard deviation, *CI* confidence interval^\*^Considered as a continuous variable

The univariate Cox proportional hazards regression model revealed that patients with an advanced T status (T4, HR = 7.100, 95% CI = 1.179--42.754, *p* = 0.032; T3, HR = 3.221, 95% CI = 0.762--13.612, *p* = 0.112), advanced N status (N2, HR = 12.896, 95% CI = 3.793--43.843, *p* \< 0.001; N1, HR = 5.267, 95% CI = 1.396--19.863, *p* = 0.014), M1 status (HR = 7.708, 95% CI = 2.957--20.095, *p \<* 0.001), late cancer stage (stage IV, HR = 18.011, 95% CI = 3.476--93.338, *p* = 0.001; stage III, HR = 4.100, 95% CI = 0.959--17.521, *p* = 0.057; stage II, HR = 0.284, 95% CI = 0.026--3.128, *p* = 0.303), lymphatic vessel invasion (HR = 3.276, 95% CI = 1.509--7.114, *p* = 0.003), venous vessel invasion (HR = 3.782, 95% CI = 1.590--8.993, *p* = 0.003), perineural invasion (HR = 3.402, 95% CI = 0.996--11.625, *p* = 0.051), a high histological grade of cancer cell malignancy (HR = 2.266, 95% CI = 1.103--4.656), and few numbers of NDLNs (≤9, HR = 2.661, 95% CI = 0.956--7.405, *p* = 0.061; 9--27, HR = 1.300, 95% CI = 0.451--3.752, *p* = 0.627) tended to have poor survival and high HRs (Table [2](#Tab2){ref-type="table"}).

We incorporated the potential variables with a log-rank *p ≤* 0.1, along with sex and age, into the multivariate Cox regression proportional hazards analysis and found that an advanced N status (N2, HR = 17.677, 95% CI = 2.048--152.605, *p* = 0.009; N1, HR = 5.749, 95% CI = 0.959--34.480, *p* = 0.056) (Fig. [1](#Fig1){ref-type="fig"}a) and M1 status (HR = 7.517, 95% CI = 1.626--34.756, *p* = 0.010) (Fig. [1](#Fig1){ref-type="fig"}b) were independently associated with a poor prognosis and high HRs in this cohort (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Fig. 1Kaplan--Meier survival curves, *p* values (log-rank test), HRs (including 95% CIs, multivariate Cox proportional hazards regression), and patients at risk based on two independent factors in CRC patients, the N status (1, **a**) and M status (1, **b**), are illustrated

Role of TDLNs/NDLNs in N(−) CRC patients {#Sec11}
----------------------------------------

The number of TDLNs is equal to the number of NDLNs in N(−) CRC patients. For all CRC patients, we determined that few NDLNs (*p* = 0.071, Table [2](#Tab2){ref-type="table"}) tended to be associated with poor survival, and we tested the cutoff number 15, the median number of NDLNs of 73 CRC patients (Table [1](#Tab1){ref-type="table"}), to evaluate its influence among 31 N(−) CRC patients. Among the 31 N(−) CRC patients, 3 (9.7%) died during the follow-up period, all of whom had nonsignificantly fewer TDLNs/NDLNs than did the other 28 patients who remained alive (13.0 ± 12.3 vs. 20.7 ± 11.5, *p* = 0.181, Table [3](#Tab3){ref-type="table"}, Part I). Two of the 3 N(−) CRC patients who died had ≤ 15 TDLNs, and 1 had \> 15 TDLNs (*p* = 0.431, Table [3](#Tab3){ref-type="table"}, Part II). In addition, N(−) CRC patients with ≤ 15 TDLNs had nonsignificantly lower 1-/2-/5-/10-/12-year survival rates and unobvious shorter survival times than those with \> 15 TDLNs (92.3%, 92.3%, 92.3%, 92.3%, and 61.5% vs. 100.0%, 93.8%, 93.8%, 93.8%, and 93.8%, respectively, and 117.0 vs. 131.6 months, respectively, *p* = 0.529, Table [3](#Tab3){ref-type="table"}, Part II). In brief, 15 TDLNs seems adequate for N(−) CRC patients, but this finding needs further validation. Table 3Differences in cumulative survival rates among the 31 N(−) CRC patients according to the current survival status and the cutoff number of TDLNs (NDLNs) of 15Part ICurrent survival statusDead (*n* = 3)Alive (*n* = 28)*p* valueNo. of TDLNs (=NDLNs) (mean ± SD)13.0 ± 12.320.7 ± 11.50.181\*Follow-up periods (mean ± SD)(month)57.1 ± 59.789.8 ± 33.90.316\*Cumulative survival rate (%) 1 year67.7%100.0% 2 years67.7%100.0% 5 years33.3%100.0% 10 years33.3%100.0% 12 years0.0%100.0%Part IITDLNs (=NDLNs)≤ 15 (*n* = 14)\> 15 (*n* = 17)*p* valueNo. of deaths (*n* = 3)210.431\*\*Follow-up periods (mean ± SD) (month)87.5 ± 41.486.0 ± 43.20.912\*Survivals (mean, 95%CI) (month)117.0 (99.3--134.7)131.6 (120.4--142.8)0.529\*\*\*Cumulative survival rate (%) 1 year92.3%100.0% 2 years92.3%93.8% 5 years92.3%93.8% 10 years92.3%93.8% 12 years61.5%93.8%*CRC* colorectal cancer, *No.* number, *TDLNs* total dissected lymph nodes, *NDLNs* negative dissected lymph nodes, *SD* standard deviation, *CI* confidence interval\*Student's *t* test/Mann--Whitey *U* test\*\*Chi-square test\*\*\*Log-rank

Distributions of TDLNs, PDLNs, and NDLNs and the positive rate for all CRC patients, CRC patients with ≤ 15 TDLNs, and CRC patients with \> 15 TDLNs according to the pathological T status {#Sec12}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The mean numbers of PDLNs among all 73 CRC patients with the T1, T2, T3, and T4 status were 0.0, 0.1, 4.1, and 7.0, respectively (*p* = 0.001), and the positive rates were 0.0%, 0.3%, 21.8%, and 24.1%, respectively (*p* = 0.001) (Table [4](#Tab4){ref-type="table"}, Part I). The numbers of TDLNs (*p* = 0.116) and NDLNs (*p* = 0.359) among CRC patients with the T1, T2, T3, and T4 statuses were not obviously different, suggesting that these LNDs were performed indiscriminately (Table [4](#Tab4){ref-type="table"}, Part I). Table 4Distributions of TDLNs, PDLNs, NDLNs, and positive rate for overall CRC patients, CRC patients with ≤ 15 TDLNs, and CRC patients with \> 15 TDLNs according to the pathological T status among the 73 CRC patientsPart IOverall (*n* = 73)T1 (*n* = 4)T2 (*n* = 9)T3 (*n* = 56)T4 (*n* = 4)*p* value\*No. of TDLNs (Mean ± SD)20.7 ± 11.821.5 ± 11.313.3 ± 10.521.3 ± 11.629.5 ± 12.90.116No. of PDLNs (Mean ± SD)3.6 ± 5.20.0 ± 0.00.1 ± 0.34.1 ± 5.47.0 ± 6.40.001Positive rate (Mean ± SD, %)18.1 ± 23.60.0 ± 0.00.3 ± 1.021.8 ± 24.624.1 ± 23.10.001No. NDLNs (Mean ± SD)17.2 ± 11.221.5 ± 11.313.2 ± 10.317.1 ± 11.322.5 ± 13.50.359Part IINo. of PDLNs (Mean ± SD)Overall (*n* = 73)T1 (*n* = 4)T2 (*n* = 9)T3 (*n* = 56)T4 (*n* = 4)No. of TDLNs ≤ 15 (*n* = 28, T1/T2/T3/T4, 2/7/19/0)1.9 ± 3.00.0 ± 0.00.0 ± 0.02.8 ± 3.3-No. of TDLNs \> 15 (*n* = 45, T1/T2/T3/T4, 2/2/37/4)4.6 ± 5.90.0 ± 0.00.5 ± 0.74.8 ± 6.17.0 ± 6.4*p* value\*\*0.0301.0000.0610.190-Part IIIPositive rate (mean ± SD, %)Overall (*n* = 73)T1 (*n* = 4)T2 (*n* = 9)T3 (*n* = 56)T4 (*n* = 5)No. of TDLNs ≤ 15 (*n* = 28, T1/T2/T3/T4, 2/7/19/0)19.5 ± 27.50.0 ± 0.00.0 ± 0.028.8 ± 29.3-No. of TDLNs \> 15 (*n* = 45, T1/T2/T3/T4, 2/2/37/4)17.2 ± 21.00.0 ± 0.01.5 ± 2.118.2 ± 21.424.1 ± 23.1*p* value\*\*0.6861.0000.0610.131-Part IVNo. of N DLNs (Mean ± SD)Overall (*n* = 73)T1 (*n* = 4)T2 (*n* = 9)T3 (*n* = 56)T4 (*n* = 5)No. of TDLNs ≤ 15 (*n* = 31, T1/T2/T3/T4, 2/7/19/0)7.7 ± 4.212.0 ± 4.28.4 ± 4.17.0 ± 4.1-No. of TDLNs \> 15 (*n* = 45, T1/T2/T3/T4, 2/2/37/4)23.1 ± 10.231.0 ± 1.430.0 ± 4.222.4 ± 10.222.5 ± 13.5*p* value\*\*\< 0.0010.0270.040\< 0.001-*No.* number, *TDLNs* total dissected lymph nodes, *PDLNs* positive dissected lymph nodes, *NDLNs* negative dissected lymph nodes, *Positive rate* No. PDLNs/No. TDLNs, %, *SD* = Standard deviation\*Compared among T1, T2, T3, and T4 status, ANOVA/Kruskal-Wallis *H* test\*\*Compared between TDLN≤ 15 and TDLN\> 15, Student's *t* test/Mann--Whitey *U* test

Concerning the number of PDLNs, those with \> 15 TDLNs tended to have more PDLNs than those with ≤ 15 TDLNs (*p* = 0.030, 4.6 ± 5.9 vs. 1.9 ± 3.0), especially those with the T2 status (*p* = 0.061, 0.5 ± 0.7 vs. 0.0 ± 0.0) (Table [4](#Tab4){ref-type="table"}, Part II). This result denotes that a minimum of 15 TDLNs is highly required to detect the N(+) status in CRC patients. Such a difference was not observed when analyzing the distribution of the positive rate (*p* = 0.686, Table [4](#Tab4){ref-type="table"}, Part III).

Concerning the number of NDLNs, those with \> 15 TDLNs tended to have more NDLNs than those with ≤ 15 TDLNs (*p \<* 0.001, 23.1 ± 10.2 vs. 7.7 ± 4.2), regardless of the T1 (*p* = 0.027, 31.0 ± 1.4 vs. 12.0 ± 4.2), T2 (*p* = 0.040, 30.0 ± 4.2 vs. 8.4 ± 4.1), or T3 (*p \<* 0.001, 22.4 ± 10.2 vs. 7.0 ± 4.1) status (Table [4](#Tab4){ref-type="table"}, Part IV).

Distributions of the mean numbers of TDLNs, PDLNs, and NDLNs and the mean positive rates in 42 N(+) CRC patients based on the number of TDLNs {#Sec13}
---------------------------------------------------------------------------------------------------------------------------------------------

The N2b status, the most advanced N status defined in the current AJCC 8th edition staging system, is defined as 7 or more PDLNs. We tested various cutoff points for TDLNs on ROC curves (AUC = 0.723, 95% CI = 0.560--0.886, *p* = 0.022), and 20.5 (i.e., 21, after rounding up 20.5) resulted in the highest Youden index of 0.459 (sensitivity = 0.769, specificity = 0.690) to distinguish between ≤ 7 and \> 7 PDLNs for all 42 N(+) CRC patients. As shown in Table [5](#Tab5){ref-type="table"}, the positive rate dropped sharply from 28.3 to 24.5% when ≥ 23/24 TDLNs was used for the 42 N(+) CRC patients. This result denotes the limitation of the positive rate during each LND, and the peak number of TDLNs did not exceed 24. Furthermore, 19 of 42 N(+) CRC patients had ≥ 21 TDLNs, and the peak positive rate (29.8%) was higher in these patients than in those with ≥ 10 \~ ≥30 TDLNs. Therefore, we propose that 21 TDLNs is sufficient. Table 5Distributions of mean numbers of TDLNs, PDLNs, and NDLNs and the mean positive rates in 42 N(+) CRC patients based on the number of TDLNsSub-groupsNo. of accumulative casesNo. of TDLNs (mean)No. of PDLNs (mean )Positive rate (Mean, %)No. of NDLNs (Mean)Overall42TDLNs ≥ 44221.26.231.515.0TDLNs ≥ 64121.66.331.015.4TDLNs ≥ 74022.06.431.415.6TDLNs ≥ 93822.86.732.316.1TDLNs ≥ 103424.46.929.517.6TDLNs ≥ 133125.87.229.118.6TDLNs ≥ 143026.37.429.918.8TDLNs ≥ 162827.17.427.719.8TDLNs ≥ 172628.07.728.620.3TDLNs ≥ 182428.97.827.821.1TDLNs ≥ 192329.48.128.521.3TDLNs ≥ 202031.08.628.822.4TDLNs ≥ 21\*1931.58.929.822.6TDLNs ≥ 231732.88.928.323.9TDLNs ≥ 241534.18.324.525.7TDLNs ≥ 251434.88.223.326.6TDLNs ≥ 271236.48.422.528.0TDLNs ≥ 281038.39.424.428.9TDLNs ≥ 29939.48.720.830.8TDLNs ≥ 30840.89.522.531.3TDLNs ≥ 34742.310.725.331.6TDLNs ≥ 35643.712.329.031.3TDLNs ≥ 36545.412.227.333.2TDLNs ≥ 41447.810.521.037.3TDLNs ≥ 47350.013.025.537.0TDLNs ≥ 51251.517.033.034.5TDLNs ≥ 52152.022.042.330.0*TDLNs* total dissected lymph nodes, PDLNs positive dissected lymph nodes, *NDLNs* negative dissected lymph nodes, *Positive rate* No. PDLNs/No. TDLNs, %, *SD* standard deviation, *CI* confidence interval, *ROC* receiver operating characteristic, *AUC* area under the curve\*We tested various cutoff points for TDLNs on ROC curves (AUC = 0.723, 95%CI = 0.560--0.886, *p* = 0.022) and 20.5 (i.e., 21, after rounding up 20.5) had the highest Youden index of 0.459 (sensitivity = 0.769, specificity = 0.690) to distinguish PDLNs ≤ 7 or PDLNs \> 7

Distributions of TDLNs, PDLNs, and NDLNs and the positive rate for N(+) CRC patients, N(+) CRC patients with ≤ 21 TDLNs, or N(+) CRC patients with \> 21 TDLNs according to the pathological N status {#Sec14}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For the 42 N(+) CRC patients, the distributions of the number of TDLNs (*p* = 0.199) and NDLNs (*p* = 0.409) were not different between those with the N1 (*n* = 17) status and those with the N2 (*n* = 25) status, suggesting that these LNDs were performed indiscriminately. The N2 CRC patients had more PDLNs (*p \<* 0.001, 9.3 ± 5.2 vs. 1.6 ± 0.7) and higher positive rates (*p \<* 0.001, 44.1 ± 20.5% vs. 12.8 ± 11.9%) than the N1 CRC patients (Table [6](#Tab6){ref-type="table"}, Part I). Table 6Distributions of TDLNs, PDLNs, and NDLNs and the positive rate for N(+) CRC patients, N(+) CRC patients with ≤ 21 TDLNs, or N(+) CRC patients with \> 21 TDLNs according to the pathological N statusPart INodal positive (*n* = 42)N1 (*n* = 17)N2 (*n* = 25)*p* value\*No. of TDLNs (mean ± SD)21.2 ± 12.018.3 ± 10.923.2 ± 12.60.199No. of PDLNs (mean ± SD)6.2 ± 5.51.6 ± 0.79.3 ± 5.2\< 0.001Positive rate (mean ± SD, %)31.5 ± 23.312.8 ± 11.944.1 ± 20.5\< 0.001No. NDLNs (mean ± SD)15.0 ± 10.616.7 ± 10.813.9 ± 10.50.409Part IINo. of PDLNs (mean ± SD)Nodal positive (*n* = 42)N1 (*n* = 17)N2 (*n* = 25)No. of TDLNs ≤ 21 (*n*=25, N1/N2, 12/13)3.4 ± 3.81.6 ± 0.76.9 ± 3.6No. of TDLNs \> 21 (*n*=17, N1/N2, 5/12)8.9 ± 6.61.6 ± 0.911.9 ± 5.4*p* value\*\*0.0070.9070.011*TDLNs* total dissected lymph nodes, *PDLNs* positive dissected lymph nodes, *NDLNs* negative dissected lymph nodes, *Positive rate* No. PDLNs/No. TDLNs, %, *SD* standard deviation\*Compared between N1 and N2 status, Student's *t* test/Mann--Whitey *U* test\*\*Compared between TDLN≤21 and TDLN\>21, Student's t test/Mann--Whitey *U* test

Concerning the number of PDLNs, those with \> 21 TDLNs tended to have more PDLNs than those with ≤ 21 TDLNs (*p* = 0.007, 8.9 ± 6.6 vs. 3.4 ± 3.8), especially those with the N2 (*p* = 0.011, 11.9 ± 5.4 vs. 6.9 ± 3.6) status (Table [6](#Tab6){ref-type="table"}, Part II). Consistent with the results described above, 21 TDLNs seemed sufficient and adequate to detect the most advanced N status (N2/N2b).

Discussion {#Sec15}
==========

Compatible with the reported literature, we demonstrated that an advanced N status and M1 status were independent variables related to a poor prognosis in this cohort (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}) \[[@CR1], [@CR7]\]. How to set an accurate N status to predict the survival of CRC patients has become an important task. In the current study, we reappraised and focused on the impacts of TDLNs on N status staging.

Similar to gastric cancer \[[@CR8]\] and esophageal cancer \[[@CR9]\], the current AJCC 8th edition staging system for CRC emphasizes the number of PDLNs and a minimal requirement of 12 TDLNs for accurate N staging. According to the equation (PDLNs = TDLNs − NDLNs), PDLNs are related to the dynamic changes in TDLNs and NDLNs. Undoubtedly, we have a higher probability of detecting the N(+) status or confirming a true N(−) status if we perform extensive LND to harvest a sufficient number of TDLNs or NDLNs. Through indiscriminant TDLNs/NDLNs among different T statuses (T1 vs. T2 vs. T3 vs. T4, *p* = 0.116/0.359, Part I, Table [4](#Tab4){ref-type="table"}), we found progressive increases in the numbers of PDLNs (*p* = 0.001) and positive rates (*p* = 0.001) in CRCs (from T1, T2, to T3, and further T4). This finding denotes a higher probability that the N(+) status could be identified in T3/T4 than in T1/T2 CRCs. In other words, the N(+) status would be underestimated as the N(−) status in T1/T2 CRCs if we do not harvest sufficient numbers of TDLNs/NDLNs for analysis.

As described in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}, we highly recommended a minimal requirement of 15 TDLNs for CRC patients undergoing primary resection. However, the cutoff value of 15 differs from the suggestion in the AJCC 8th edition staging system. Different cutoff values of TDLNs were also reported in other series, and potential differences in race, surgeons, types of surgical resection, and statistics might account for such differences \[[@CR10]--[@CR12]\]. Nevertheless, the main aims of these reported articles were similar, and all paid attention to the minimal requirement of TDLNs to detect the N(+) status or to avoid understaging N(−) patients.

Another important issue is to what extent LND can be performed. As described in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, we found that 21 TDLNs seemed sufficient to detect the most advanced N(+) status, N2b, in N(+) CRC patients. Baxter et al. used the "ceiling effect" to explain the phenomenon underlying the positive rate reported in Table [5](#Tab5){ref-type="table"} \[[@CR12], [@CR13]\]. In the literature, few studies have discussed the extent of TDLNs for N(+) patients. Despite the poor prognosis associated with an advanced N2b status, chemotherapy, radiotherapy, immunotherapy, or all treatments can be tailored and advocated if the N(+) status is classified accurately.

In the literature, large numbers of NDLNs were reported to be associated with prolonged survival in patients with ESCC, gastric cancer, or CRC \[[@CR14]--[@CR17]\]. Compatible with these results, our preliminary results also demonstrated that a large number of NDLNs was related to prolonged survival among the 73 CRC patients (*p* = 0.071, subgrouped, ≤ 9, 9--25, and \> 25, Table [2](#Tab2){ref-type="table"}). This result indicates that a large number of NDLNs is related to prolonged survival in CRC patients, and a minimal requirement of 9 NDLNs has been reported by Quan et al \[[@CR16]\]. However, the prognostic impact of NDLNs was excluded when PDLNs were defined according to the N status (AJCC 8th edition staging system, N0, N1, and N2) after multivariate Cox regression proportional hazards analysis (Table [2](#Tab2){ref-type="table"}). Such a situation is usually encountered in clinical practice when we are concerned about nodal condition from the viewpoint of PDLNs/TDLNs simultaneously. For example, when CRC patients experience nodal conditions such as those in case A (1/10 \[PDLNs/TDLNs\] \[N1a\]) vs. case B (4/20 \[N2a\]), most surgeons believe that case B might have a worse prognosis due to a later N status although case B has a larger number of NDLNs. As we demonstrated, the number of PDLNs has a greater effect on survival than the number of NDLNs. In contrast, when CRC patients experience nodal conditions such as those in case C: 1/10 (N1a) vs. case D: 1/20 (N1a), most surgeons believe that the N1a status of case D is more accurate than that of case C because case C might be understaged due to fewer NDLNs. As a result, we believe that in a situation with the same number of PDLNs, a large number of NDLNs denotes more accurate N status staging. However, the minimal requirement of NDLNs remains unclear. To simplify this problem, we found that the number of NDLNs was highly related to the number of TDLNs in our cohort (*p \<* 0.001, Pearson's correlation coefficient = 0.900, data not shown). Therefore, we suggest that a minimum of 15 TDLNs is necessary to differentiate the N(−) or N(+) status in CRC patients and that 21 TDLNs seem sufficient to detect the severity of N status staging in N(+) CRC patients.

Some authors have reported that right hemicolectomy may harvest more TDLNs than other types of resection and argued that the minimal requirement of TDLNs be based on the regions of vascular pedicles to be ligated \[[@CR18], [@CR19]\]. Compatible with these findings, we found that the mean numbers of TDLNs harvested from segmental resection, right hemicolectomy, left hemicolectomy, anterior resection, lower anterior resection, subtotal resection, abdominal-perineal resection, and Hartmann's procedure were 11.5, 29.0, 16.0, 22.2, 16.6, 21.0, 6.5, and 9.0, respectively, with right hemicolectomy (29.0) harvesting the largest number of TDLNs (*p \<* 0.001, data not shown). Nevertheless, the mean numbers of PDLNs were 4.5, 3.2, 5.8, 1.2, 3.7, 7.0, 2.0, and 5.3, respectively, without obvious differences (*p* = 0.715, data not shown), suggesting that the type of surgery has no significant impact on N status staging. Whether the minimal requirement of TDLNs should be revised according to different vascular pedicles remains under debate. We need additional clinical data for validation in the future.

This study does offer relevant information for colorectal surgeons and oncologists. Nevertheless, there are several limitations, including the small sample size and the fact that this was a retrospective analysis from a single medical institution. More case numbers recruited from multiple centers or nationwide databases are necessary for further study.

Conclusion {#Sec16}
==========

In conclusion, a sufficient number of TDLNs is an important checkpoint for the adequate N status staging of CRC patients.
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